Amgen Gets FTC Go-Ahead for $27.8 Billion Horizon Deal

The US Federal Trade Commission has allowed Amgen to continue its $27.8 billion acquisition of Horizon Therapeutics.
Reuters Health Information

source https://www.medscape.com/s/viewarticle/996061?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost